tbuckley/cabot-search huggingface dataset:
Cardiac Dyssynchrony in Congestive Heart Failure and Atrial Fibrillation: Integrating Regularization and Resynchronization⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Jozef Bartunek, Marc Vanderheyden
Journal: Journal of the American College of Cardiology (2008)
Real‐world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006–2019
Authors: Hsu‐Chih Chien, Deborah Morreall, Vikas Patil, Kelli M. Rasmussen, Christina M. Yong, Chun‐Yang Li, Deborah G. Passey, Zachary Burningham, Brian C. Sauer, Ahmad S. Halwani
Journal: American Journal of Hematology (2021)
Evaluation of Biventricular Functions in Patients With Covid-19 Using Speckle Tracking Echocardiography
Authors: O. F. Baycan, H. A. A. Barman, A. Atici, M. A. Tatlisu, F. Bolen, P. Ergen, S. Icten, B. Gungor, M. Caliskan
Journal: Circulation (2020)
What's True in Truth and Reconciliation? Why Epistemic Justice is of Paramount Importance in Addressing Structural Racism in Healthcare
Authors: Yoann Della Croce, Matteo Gianni, Valeria Marino
Journal: The American Journal of Bioethics (2021)

In their address of structural racism in healthcare, Sabatello and colleagues (2021) provide both a remarkable review of the empirical literature regarding the disproportionate impacts of the COVID...
Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial
Authors: Alaknanda Mishra, Camasamudram Vijayasarathy, Catherine A. Cukras, Henry E. Wiley, H. Nida Sen, Yong Zeng, Lisa L. Wei, Paul A. Sieving
Journal: Molecular Therapy (2021)

This study explored systemic immune changes in 11 subjects with X-linked retinoschisis (XLRS) in a phase I/IIa adeno-associated virus 8 (AAV8)-RS1 gene therapy trial (ClinicalTrials.gov: NCT02317887). Immune cell proportions and serum analytes were compared to 12 healthy male controls. At pre-dosing baseline the mean CD4/CD8 ratio of XLRS subjects was elevated. CD11c+ myeloid dendritic cells (DCs) and the serum epidermal growth factor (EGF) level were decreased, while CD123+ plasmacytoid DCs and serum interferon (IFN)-γ and tumor necrosis factor (TNF)-α were increased, indicating that the XLRS baseline immune status differs from that of controls. XLRS samples 14 days after AAV8-RS1 administration were compared with the XLRS baseline. Frequency of CD11b+CD11c+ DCc was decreased in 8 of 11 XLRS subjects across all vector doses (1e9-3e11 vector genomes [vg]/eye). CD8+human leukocyte antigen-DR isotype (HLA-DR)+ cytotoxic T cells and CD68+CD80+ macrophages were upregulated in 10 of 11 XLRS subjects, along with increased serum granzyme B in 8 of 11 XLRS subjects and elevated IFN-γ in 9 of 11 XLRS subjects. The six XLRS subjects with ocular inflammation after vector application gave a modestly positive correlation of inflammation score to their respective baseline CD4/CD8 ratios. This exploratory study indicates that XLRS subjects may exhibit a proinflammatory, baseline immune phenotype, and that intravitreal dosing with AAV8-RS1 leads to systemic immune activation with an increase of activated lymphocytes, macrophages, and proinflammatory cytokines.
Re: Paolo Dell’Oglio, Hielke M. de Vries, Elio Mazzone, et al. Hybrid Indocyanine Green–99mTc-nanocolloid for Single-photon Emission Computed Tomography and Combined Radio- and Fluorescence-guided Sentinel Node Biopsy in Penile Cancer: Results of 740 Inguinal Basins Assessed at a Single Institution. Eur Urol 2020;78:865–72
Authors: Christian D. Fankhauser, Arie Parnham, Vijay Sangar
Journal: European Urology (2021)
Reducing contacts to stop SARS-CoV-2 transmission during the second pandemic wave in Brussels, Belgium, August to November 2020
Authors: Brecht Ingelbeen, Laurène Peckeu, Marie Laga, Ilona Hendrix, Inge Neven, Marianne AB van der Sande, Esther van Kleef
Journal: Eurosurveillance (2021)

To evaluate the effect of physical distancing and school reopening in Brussels between August and November 2020, we monitored changes in the number of reported contacts per SARS-CoV-2 case and associated SARS-CoV-2 transmission. The second COVID-19 pandemic wave in Brussels was the result of increased social contact across all ages following school reopening. Physical distancing measures including closure of bars and restaurants, and limiting close contacts, while primary and secondary schools remained open, reduced social mixing and controlled SARS-CoV-2 transmission.
Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer
Authors: Jiawei Zhou, Quefeng Li, Yanguang Cao
Journal: Cancer Research (2021)

The sum of target lesions is routinely used to evaluate patient objective responses to treatment in the RECIST criteria, but it fails to address response heterogeneity across metastases. This study argues that spatiotemporal heterogeneity across metastases and organ-specific response is informative for drug efficacy and patient survival. We analyzed the longitudinal data of 11,404 metastatic lesions in 2,802 colorectal cancer patients from five phase III clinical trials. Initially, a metric Gower distance was applied to quantify response heterogeneity across metastases. Next, the spatiotemporal response heterogeneity across anatomic sites, therapies, and KRAS mutation status was assessed and examined for its association with drug efficacy and long-term patient survival. The response of metastatic lesions broadly differed across anatomic sites and therapies. About 60% of patients had at least one lesion respond contrarily from total tumor size. High interlesion heterogeneity was associated with shorter progression-free survival and overall survival. Targeted therapies (bevacizumab or panitumumab) combined with standard chemotherapy reduced interlesion heterogeneity and elicited more favorable effects from liver lesions (P < 0.001) than chemotherapy alone. Moreover, the favorable responses in liver metastases (> 30% shrinkage) were associated with extended patient overall survival (P < 0.001), in contrast to lesions in the lungs and lymph nodes. Altogether, the spatiotemporal response heterogeneity across metastases informed drug efficacy and patient survival, which could improve the current methods for treatment evaluation and patient prognosis. SIGNIFICANCE: These findings support the modification of RECIST criteria to include individual lesion response to improve assessments of drug efficacy.
Prevention of heart failure events with sodium–glucose co‐transporter 2 inhibitors across a spectrum of cardio‐renal‐metabolic risk
Authors: Kirtipal Bhatia, Vardhmaan Jain, Kartik Gupta, Agam Bansal, Arieh Fox, Arman Qamar, Kevin Damman, Muthiah Vaduganathan
Journal: European Journal of Heart Failure (2021)
Vasovagal Syncope—Reply
Authors: Elizabeth R. Doman, Adam J. Kisling, Emilio Fentanes
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
<i>QuickStats</i>: Age-Adjusted Death Rates* from Dementia,<sup>†</sup> by Sex, Race, and Hispanic Origin — National Vital Statistics System, United States, 2017
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Age-adjusted death rates are per 100,000 population and are based on the 2000 U.S. standard population.† Dementia deaths are identified according to the International Classification of Diseases, Tenth Revision underlying cause-of-death codes: F03 (unspecified dementia), G30 (Alzheimer's disease), F01 (vascular dementia), and G31 (other degenerative diseases of nervous system).In 2017, age-adjusted death rates for dementia were higher among non-Hispanic white persons compared with non-Hispanic black and Hispanic persons (70.8 per 100,000 compared with 65.0 and 46.0, respectively).Also, among women, the rates were highest among non-Hispanic white women (77.6) compared with non-Hispanic black women (67.4) and Hispanic women (49.8).The age-adjusted death rate for non-Hispanic white men was not statistically different from the rate for non-Hispanic black men (59.4 compared with 58.8).Age-adjusted death rates were higher for women than men among non-Hispanic white, non-Hispanic black, and Hispanic populations.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Authors: Tina Cascone, William N. William, Annikka Weissferdt, Cheuk H. Leung, Heather Y. Lin, Apar Pataer, Myrna C. B. Godoy, Brett W. Carter, Lorenzo Federico, Alexandre Reuben, Md Abdul Wadud Khan, Hitoshi Dejima, Alejandro Francisco-Cruz, Edwin R. Parra, Luisa M. Solis, Junya Fujimoto, Hai T. Tran, Neda Kalhor, Frank V. Fossella, Frank E. Mott, Anne S. Tsao, George Blumenschein, Xiuning Le, Jianjun Zhang, Ferdinandos Skoulidis, Jonathan M. Kurie, Mehmet Altan, Charles Lu, Bonnie S. Glisson, Lauren Averett Byers, Yasir Y. Elamin, Reza J. Mehran, David C. Rice, Garrett L. Walsh, Wayne L. Hofstetter, Jack A. Roth, Mara B. Antonoff, Humam Kadara, Cara Haymaker, Chantale Bernatchez, Nadim J. Ajami, Robert R. Jenq, Padmanee Sharma, James P. Allison, Andrew Futreal, Jennifer A. Wargo, Ignacio I. Wistuba, Stephen G. Swisher, J. Jack Lee, Don L. Gibbons, Ara A. Vaporciyan, John V. Heymach, Boris Sepesi
Journal: Nature Medicine (2021)
Abstract SP027: Treatment differences and consequences
Authors: M Chavez Mac Gregor
Journal: Cancer Research (2021)

Abstract Breast cancer is the deadliest cancer among women worldwide, with a total of over half a million deaths annually impacting both developed and developing countries. With an estimated 276,480 breast cancer cases projected to occur in women in the U.S., it is estimated that 42,170 women will die in 2020 due to this devastating disease. Despite the decrease in breast cancer mortality rates seen in recent years, the magnitude of that decrease in not similar across populations. In the U.S the burden of cancer is not shouldered equally. It is well known that racial and ethnic minority populations are more likely to experience cancer health disparities. While potential contributing factors associated with this phenomenon include the fact that certain groups of patients are more likely to be diagnosed with more advanced stages and to have tumors with more aggressive biology, sociodemographic factors and difficulty accessing medical care play an important role. Unfortunately, cancer care delivery is not the same for all and this can seriously hinder the cancer outcomes of those affected. Across the cancer care continuum -from screening, diagnosis, and all the way to treatment, survivorship or end-of life care-, important disparities exist leading to worse outcomes. It has been well described that Black and Hispanic women are less likely to receive appropriate and timely breast cancer treatment. Furthermore, the complex, and in many cases long treatments needed to achieve the desired outcomes, force patients to face issues associated with navigating the health care system, making life changes to accommodate treatment, and ensuring continuation and treatment adherence. In this presentation, we will review the complexities of breast cancer diagnosis and treatment and review some of the data regarding the detrimental impact associated to treatment delays. Improving cancer care delivery and ensuring access to timely and high-quality care should be a priority. We will briefly revise some of the strategies designed to overcome health disparities and hopefully, improve breast cancer outcomes. Citation Format: M Chavez Mac Gregor. Treatment differences and consequences [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SP027.
Abstract PS10-13: Impact of trastuzumab on Ipsilateral breast tumor recurrence after breast conserving surgery
Authors: Jong Ho Cheun, Han-Byoel Lee, Hyeong-Gon Moon, Dong-Young Noh, Wonshink Han
Journal: Cancer Research (2021)

Abstract Background: Trastuzumab is well known to be effective to control locoregional recurrence and distant metastasis of human epidermal growth factor receptor 2 (HER2)-overexpressing breast tumor. However, few studies have reported the effect of ipsilateral breast tumor recurrence (IBTR) in spite of higher incidence of IBTR for HER2 overexpressing subtype than other subtypes. The purpose of this study is to investigate the difference in the incidence of IBTR of HER2-overexpressing breast tumor according to adjuvant trastuzumab. Methods: We retrospectively reviewed 996 patients who had done surgery for HER2-overexpressing breast cancer between January 2000 and December 2017 in our institution. Patients with tumors smaller than 0.5cm without axillar node metastasis were excluded. As regarding IBTR as recurrence “in” the ipsilateral breast, only patients who had done breast conserving surgery were included. Results: There were 735 patients who had finished adjuvant trastuzumab as first planned and 555 patients with hormone receptor positive. Median follow-up period for all patients was 70.7 months (range 12.7-239.6 months). The 10-year IBTR-free survival rate showed a significant benefit for the group treatment with trastuzumab than the group without trastuzumab (97.0% versus 91.9%; p=0.007). In a multivariate analysis, presence of lymphovascular invasion (Hazard ratio [HR], 2.53; 95% Confidence interval [CI], 1.19 - 5.41), closed or involved resection margin (HR, 2.62; 95% CI, 1.20 - 5.74), positive hormone receptor (HR, 3.70; 95% CI, 1.69 - 8.08), positive axillar lymph node (HR, 5.21; 95% CI, 1.75 - 15.57), and omitted or uncompleted adjuvant trastuzumab (HR, 2.72; 95% CI, 1.11 - 6.67) were independent predictors of IBTR. However, subgroup analysis of the patients with hormone receptor negative tumor showed no benefit of adjuvant trastuzumab (98.1% versus 96.6%, p=0.669) while it controlled IBTR for hormone receptor positive tumor (95.7% versus 86.2%; p=0.002). When additionally analzyed, trastuzumab showed benefit for 10-year locoregional recurrence-free survival (95.5% versus 89.7%, p=0.012) and distant metastasis-free survival (93.5% versus 77.8%, p&amp;lt;0.001). Conclusions: Trastuzumab has a clinical benefit in not only locoregional recurrence but also IBTR among HER2-overexpression breast cancer, especially with negative hormone receptor. Citation Format: Jong Ho Cheun, Han-Byoel Lee, Hyeong-Gon Moon, Dong-Young Noh, Wonshink Han. Impact of trastuzumab on Ipsilateral breast tumor recurrence after breast conserving surgery [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS10-13.
Abstract 1327: Beneficial Effects of Physical Exercise on Myocardial Telomere Regulating Proteins, Survival Pathways and Apoptosis
Authors: Milad Hanhoun, Thomas Widmann, Andrey Kazakov, Patrick Müller, Michael Böhm, Ulrich Laufs
Journal: Circulation (2007)

Background: Physical exercise is associated with positive cardiovascular effects, but the underlying molecular mechanisms are incompletely understood. Telomere-regulating proteins have been shown t...
Genotoxicity of acrylamide in humans and mice: Promutagenic glycidamide-DNA adducts in the human p53 gene and the cII transgene
Authors: Ahmad Besaratinia, Gerd P. Pfeifer
Journal: Cancer Research (2004)

1968  The recent discovery of acrylamide in a variety of food products has raised concern for public health worldwide. Acrylamide is a proven rodent carcinogen, which finds its way into the human diet when amino acids and sugars present in foods are heated at high temperature i.e., during food processing such as frying. Substantial quantities of acrylamide are found in commonly consumed foods e.g., breakfast cereals, French fries and potato chips, or beverages e.g., coffee. Although it has long been known that administration of acrylamide in laboratory animals results in tumor formation at various organs, the mechanism by which acrylamide exerts this effect remains unclear. We addressed this issue by investigating the biological and biochemical fates of acrylamide and its epoxide derivative, glycidamide, administered in vitro in human bronchial epithelial cells as well as in transgenic mouse embryonic fibroblasts. We quantified the formation and repair of DNA adducts along the human p53 gene and the cII transgene by terminal transferase-dependent polymerase chain reaction, and the frequency and spectrum of induced cII mutations by a lambda phage-based mutation detection system and DNA sequencing analysis, respectively. Both acrylamide and glycidamide formed bulky DNA adducts at specific locations along the p53 and cII genes. Saturation of DNA-adduct formation was observed for some acrylamide-DNA adducts, whereas all glycidamide-DNA adducts were dose-dependent. Although the majority of the induced-DNA adducts was repaired within 24-48 hours after treatments, there were persistent acrylamide- and glycidamide-DNA adducts at specific codons along exons 5, 6, and 7 of the p53 gene as well as at particular nucleotide positions along the cII gene. Both acrylamide- and glycidamide-treatments increased significantly the frequency of the cII mutations relative to control treatment (solvent double-distilled water) (P
EFFECT OF DOSE ON EFFICACY AND SAFETY IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA - RESULTS FROM A PHASE II, RANDOMIZED, DOSE-RANGING STUDY
Authors: Celeste Lebbe, Axel Hoos, Kevin Chin, J. Li, Bart Neyns, Gerald Linette, Sylvie Negrier, Dirk Schadendorf, Michael Smylie, Jedd D. Wolchock
Journal: Annals of Oncology (2008)
Response to ‘Correspondence on ‘Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis’’ by Reuter<i>et al</i>
Authors: Chanakya Sharma, Samuel Whittle, Pari Delir Haghighi, Frada Burstein, Helen Isobel Keen
Journal: Annals of the Rheumatic Diseases (2021)

We would like to thank Reuter et al for their interest in our study and the constructive spirit in which their comments were offered.1 ,2 We agree with their concerns about inferring causality, which we have not done. Our study was designed to help provide coherence to the plethora of online discussions about disease-modifying antirheumatic drugs (DMARDs) but was not intended to imply causality. We also agree with their concerns regarding the veracity of the data collected from social media forums …
A public health approach for deciding policy on infant feeding and mother–infant contact in the context of COVID-19
Authors: Nigel Rollins, Nicole Minckas, Fyezah Jehan, Rakesh Lodha, Daniel Raiten, Claire Thorne, Philippe Van de Perre, Mija Ververs, Neff Walker, Rajiv Bahl, Cesar G Victora
Journal: The Lancet Global Health (2021)

The COVID-19 pandemic has raised concern about the possibility and effects of mother-infant transmission of SARS-CoV-2 through breastfeeding and close contact. The insufficient available evidence has resulted in differing recommendations by health professional associations and national health authorities. We present an approach for deciding public health policy on infant feeding and mother-infant contact in the context of COVID-19, or for future emerging viruses, that balances the risks that are associated with viral infection against child survival, lifelong health, and development, and also maternal health. Using the Lives Saved Tool, we used available data to show how different public health approaches might affect infant mortality. Based on existing evidence, including population and survival estimates, the number of infant deaths in low-income and middle-income countries due to COVID-19 (2020-21) might range between 1800 and 2800. By contrast, if mothers with confirmed SARS-CoV-2 infection are recommended to separate from their newborn babies and avoid or stop breastfeeding, additional deaths among infants would range between 188 000 and 273 000.
Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis
Authors: Shuo Zhang, Zhen Chen, Puyu Shi, Songqing Fan, Yong He, Qiming Wang, Yixiang Li, Suresh S. Ramalingam, Taofeek K. Owonikoko, Shi-Yong Sun
Journal: Theranostics (2021)

Death receptor 4 (DR4), a cell surface receptor, mediates apoptosis or induces inflammatory cytokine secretion upon binding to its ligand depending on cell contexts. Its prognostic impact in lung cancer and connection between EGFR-targeted therapy and DR4 modulation has not been reported and thus was the focus of this study. Methods: Intracellular protein alterations were measured by Western blotting. Cell surface protein was detected with antibody staining and flow cytometry. mRNA expression was monitored with qRT-PCR. Gene transactivation was analyzed with promoter reporter assay. Drug dynamic effects in vivo were evaluated using xenografts. Gene modulations were achieved with gene overexpression and knockdown. Proteins in human archived tissues were stained with immunohistochemistry. Results: EGFR inhibitors (e.g., osimertinib) decreased DR4 levels only in EGFR mutant NSCLC cells and tumors, being tightly associated with induction of apoptosis. This modulation was lost once cells became resistant to these inhibitors. Increased levels of DR4 were detected in cell lines with acquired osimertinib resistance and in NSCLC tissues relapsed from EGFR-targeted therapy. DR4 knockdown induced apoptosis and augmented apoptosis when combined with osimertinib in both sensitive and resistant cell lines, whereas enforced DR4 expression significantly attenuated osimertinib-induced apoptosis. Mechanistically, osimertinib induced MARCH8-mediated DR4 proteasomal degradation and suppressed MEK/ERK/AP-1-dependent DR4 transcription, resulting in DR4 downregulation. Moreover, we found that DR4 positive expression in human lung adenocarcinoma was significantly associated with poor patient survival. Conclusions: Collectively, we suggest that DR4 downregulation is coupled to therapeutic efficacy of EGFR-targeted therapy and predicts improved prognosis, revealing a previously undiscovered connection between EGFR-targeted therapy and DR4 modulation.
Presence of Myocardial Injury on Admission is Associated With an Increase in All-cause Mortality in Patients With COVID-19
Authors: Z. Ahmed, A. Singh, L. Vadlamani, M. Eder, Z. Ghazizadeh, J. Park, M. Pareek, J. Pacor, C. Gier, C. Mena-hurtado, E. J. Velazquez, N. R. Desai
Journal: Circulation (2020)
Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8
Authors: Yunjiao Zhang, Xiaowan Huang, Liansheng Wang, Cong Cao, Hao Zhang, Pengfei Wei, He Ding, Yang Song, Ziying Chen, Jieying Qian, Suqin Zhong, Zefeng Liu, Meimei Wang, Wenbin Zhang, Wenwei Jiang, Jie Zeng, Guangyu Yao, Long-ping Wen
Journal: Biomaterials (2021)